Cargando…

Essential medicines for reproductive health: developing evidence based interagency list

Objectives: Although poor reproductive health constitutes a significant proportion of the disease burden in developing countries, essential medicines for reproductive health are often not available to the population. The objective was to analyze the guiding principles for developing national Essenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Logez, Sophie, Jayasekar, Shalini, Moller, Helene, Ahmed, Kabir, Patel, Margaret Usher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dr. Zaheer-Ud-Din Babar 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471179/
https://www.ncbi.nlm.nih.gov/pubmed/23093884
http://dx.doi.org/10.5655/smr.v4i2.1003
_version_ 1782246381978648576
author Logez, Sophie
Jayasekar, Shalini
Moller, Helene
Ahmed, Kabir
Patel, Margaret Usher
author_facet Logez, Sophie
Jayasekar, Shalini
Moller, Helene
Ahmed, Kabir
Patel, Margaret Usher
author_sort Logez, Sophie
collection PubMed
description Objectives: Although poor reproductive health constitutes a significant proportion of the disease burden in developing countries, essential medicines for reproductive health are often not available to the population. The objective was to analyze the guiding principles for developing national Essential Medicines Lists (EML). The second objective was to compare the reproductive health medicines included on these EMLs to the 2002 WHO/UNFPA list of essential drugs and commodities for reproductive health. Another objective was to compare the medicines included in existing international lists of medicines for reproductive health. Methods: The authors calculated the average number of medicines per clinical groups included in 112 national EMLs and compared these average numbers with the number of medicines per clinical group included on the WHO/UNFPA List. Additionally, they compared the content of the lists of medicines for reproductive health developed by various international agencies. Results: In 2003, the review of the 112 EMLs highlighted that medicines for reproductive health were not consistently included. The review of the international lists identified inconsistencies in their recommendations. The reviews’ outcomes became the catalyst for collaboration among international agencies in the development of the first harmonized Interagency List of Essential Medicines for Reproductive Health. Additionally, WHO, UNFPA and PATH published guidelines to support the inclusion of essential medicines for reproductive health in national medicine policies and EMLs. The Interagency List became a key advocacy tool for countries to review their EMLs. In 2009, a UNFPA/WHO assessment on access to reproductive health medicines in six countries demonstrated that the major challenge was that the Interagency List had not been updated recently and was inconsistently used. Conclusion: The addition of cost-effective medicines for reproductive health to EMLs can result in enhanced equity in access to and cost containment of these medicines, and improve quality of care. Action is required to ensure their inclusion in national budget lines, supply chains, policies and programmatic guidance.
format Online
Article
Text
id pubmed-3471179
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dr. Zaheer-Ud-Din Babar
record_format MEDLINE/PubMed
spelling pubmed-34711792012-10-23 Essential medicines for reproductive health: developing evidence based interagency list Logez, Sophie Jayasekar, Shalini Moller, Helene Ahmed, Kabir Patel, Margaret Usher South Med Rev Review Article Objectives: Although poor reproductive health constitutes a significant proportion of the disease burden in developing countries, essential medicines for reproductive health are often not available to the population. The objective was to analyze the guiding principles for developing national Essential Medicines Lists (EML). The second objective was to compare the reproductive health medicines included on these EMLs to the 2002 WHO/UNFPA list of essential drugs and commodities for reproductive health. Another objective was to compare the medicines included in existing international lists of medicines for reproductive health. Methods: The authors calculated the average number of medicines per clinical groups included in 112 national EMLs and compared these average numbers with the number of medicines per clinical group included on the WHO/UNFPA List. Additionally, they compared the content of the lists of medicines for reproductive health developed by various international agencies. Results: In 2003, the review of the 112 EMLs highlighted that medicines for reproductive health were not consistently included. The review of the international lists identified inconsistencies in their recommendations. The reviews’ outcomes became the catalyst for collaboration among international agencies in the development of the first harmonized Interagency List of Essential Medicines for Reproductive Health. Additionally, WHO, UNFPA and PATH published guidelines to support the inclusion of essential medicines for reproductive health in national medicine policies and EMLs. The Interagency List became a key advocacy tool for countries to review their EMLs. In 2009, a UNFPA/WHO assessment on access to reproductive health medicines in six countries demonstrated that the major challenge was that the Interagency List had not been updated recently and was inconsistently used. Conclusion: The addition of cost-effective medicines for reproductive health to EMLs can result in enhanced equity in access to and cost containment of these medicines, and improve quality of care. Action is required to ensure their inclusion in national budget lines, supply chains, policies and programmatic guidance. Dr. Zaheer-Ud-Din Babar 2011-12-02 /pmc/articles/PMC3471179/ /pubmed/23093884 http://dx.doi.org/10.5655/smr.v4i2.1003 Text en
spellingShingle Review Article
Logez, Sophie
Jayasekar, Shalini
Moller, Helene
Ahmed, Kabir
Patel, Margaret Usher
Essential medicines for reproductive health: developing evidence based interagency list
title Essential medicines for reproductive health: developing evidence based interagency list
title_full Essential medicines for reproductive health: developing evidence based interagency list
title_fullStr Essential medicines for reproductive health: developing evidence based interagency list
title_full_unstemmed Essential medicines for reproductive health: developing evidence based interagency list
title_short Essential medicines for reproductive health: developing evidence based interagency list
title_sort essential medicines for reproductive health: developing evidence based interagency list
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471179/
https://www.ncbi.nlm.nih.gov/pubmed/23093884
http://dx.doi.org/10.5655/smr.v4i2.1003
work_keys_str_mv AT logezsophie essentialmedicinesforreproductivehealthdevelopingevidencebasedinteragencylist
AT jayasekarshalini essentialmedicinesforreproductivehealthdevelopingevidencebasedinteragencylist
AT mollerhelene essentialmedicinesforreproductivehealthdevelopingevidencebasedinteragencylist
AT ahmedkabir essentialmedicinesforreproductivehealthdevelopingevidencebasedinteragencylist
AT patelmargaretusher essentialmedicinesforreproductivehealthdevelopingevidencebasedinteragencylist